Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma

Cancer

Volumn 110, Issue 1, 2007, Pages 87-95

  Zhang, Chun Ye ^a   Mao, Li ^b,c   Li, Lei ^a   Tian, Zhen ^a   Zhou, Xiao Jian ^a   Zhang, Zhi Yuan ^a   Li, Jiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Carcinogenesis; E cadherin; Gene inactivation; Promoter methylation; Salivary gland adenoid cystic carcinoma

Indexed keywords

AZACITIDINE; MESSENGER RNA; UVOMORULIN;

ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND CARCINOMA; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; CADHERINS; CARCINOMA, ADENOID CYSTIC; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVARY GLAND NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 34347220920     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22758     Document Type: Article

References (44)

1. Ellis GL, Auclair PL. Tumors of the salivary glands. In: Ellis GL, Auclair PL, eds. Altas of Tumor Pathology, 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1996: 57-68, 337-343.
2. Dardick I. Adenoid cystic carcinoma. In: Dardick I, ed. Color Atlas/Text of Salivary Gland Tumor Pathology. New York, NY: IGAKU-SHOIN Medical Publishers; 1996:149-161.
3. Li J, Wang BY, Nelson M, et al. Salivary adenocarcinoma, not otherwise specified: a collection of orphans. Arch Pathol Lab Med. 2004;128:1385-1394.
4. Rapidis AD, Givalos N, Gakiopoulou H, et al. Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol. 2005;41:328-335.
5. Sung MW, Kim KH, Kim JW, et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003;129:1193-1197.
6. Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96:149-158.
7. Nascimento AG, Amaral AL, Prado LA, Kligerman J, Silveira TR. Adenoid cystic carcinoma of salivary glands. A study of 61 cases with clinicopathologic correlation. Cancer. 1986;57:312-319.
8. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg. 1974;128:512-520.
9. Kim KH, Sung MW, Chung PS, Rhee CS, Park CI, Kim WH. Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1994;120:721-726.
10. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma: factors influencing survival. Am J Surg. 1979;138:579-583.
11. Kwon GY, Yoo BC, Koh KC, Cho JW, Park WS, Park CK. Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules. J Korean Med Sci. 2005;20:242-247.
12. Tozawa T, Tamura G, Honda T, et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci. 2004;95:736-740.
13. Lee JK, Kim MJ, Hong SP, Hong SD. Inactivation patterns of p16/INK4A in oral squamous cell carcinomas. Exp Mol Med. 2004;36:165-171.
14. Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:2362-2368.
15. Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res. 2002;8:3164-3171.
16. Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001;92:2760-2768.
17. Seike M, Gemma A, Hosoya Y, et al. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. Clin Cancer Res. 2000;6:4307-4313.
18. Yang Q, Zage P, Kagan D, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res. 2004;10:8493-8500.
19. Li J, El-Naggar A, Mao L. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer. 2005;104:771-776.
20. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333-339.
21. Mareel M, Boterberg T, Noe V, et al. E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol. 1997;173:271-274.
22. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251:1451-1455.
23. Sasatomi E, Tokunaga O, Miyazaki K. Spontaneous apoptosis in gallbladder carcinoma. Relationships with clinicopathologic factors, expression of E-cadherin, bcl-2 protooncogene, and p53 oncosuppressor gene. Cancer. 1996;78:2101-2110.
24. Hermiston ML, Gordon JI. In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death. J Cell Biol. 1995;129:489-506.
25. Cowin P. Unraveling the cytoplasmic interactions of the cadherin superfamily. Proc Natl Acad Sci USA. 1994;91:10759-10761.
26. Kim HC, Kim HJ, Kim JC. Reduced E-cadherin expression as a cause of distinctive signet-ring cell variant in colorectal carcinoma. J Korean Med Sci. 2002;17:23-28.
27. Garcia del Muro X, Torregrosa A, Munoz J, et al. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer. 2000;36:357-362.
28. Huiping C, Sigurgeirsdottir JR, Jonasson JG, et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer. 1999;81:1103-1110.
29. Hoteiya T, Hayashi E, Satomura K, Kamata N, Nagayama M. Expression of E-cadherin in oral cancer cell lines and its relationship to invasiveness in SCID mice in vivo. J Oral Pathol Med. 1999;28:107-111.
30. Kanai Y, Oda T, Tsuda H, Ochiai A, Hirohashi S. Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res. 1994;85:1035-1039.
31. Graziano F, Arduini F, Ruzzo A, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol. 2004;15:489-492.
32. Sarrio D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003;106:208-215.
33. Guan XF, Qiu WL, He RG, Lin GC, Zhang XJ. The selection of high lung metastasis salivary adenoid cystic carcinoma clone. Chin J Stomatol. 1996;3:74-77.
34. He RG, Zhang XS, Zhou XJ, Wang Z, Zhang XL, Qiu WL. The establishment of cell lines of adenoid cystic carcinoma of human salivary glands (ACC-2, ACC-3) and a study of morphology. West China J Stomatol. 1988;6:1-4.
35. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors, 6th ed. New York, NY: John Wiley & Sons; 2002.
36. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res. 2004;10:2401-2406.
37. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002;62:3698-3701.
38. Riese U, Dahse R, Fiedler W, et al. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int J Mol Med. 1999;4:61-65.
39. Elisei R, Shiohara M, Koeffler HP, Fagin JA. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer. 1998;83:2185-2193.
40. Maruya S, Kurotaki H, Wada R, Saku T, Shinkawa H, Yagihashi S. Promoter methylation and protein expression of the E-cadherin gene in the clinicopathologic assessment of adenoid cystic carcinoma. Mod Pathol. 2004;17:637-645.
41. Kulkarni V, Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol. 2004;40:145-153.
42. Saito T, Nishimura M, Yamasaki H, Kudo R. Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferentiation and myometrial invasion in endometrial carcinoma. Cancer. 2003;97:1002-1009.
43. Nakayama S, Sasaki A, Mese H, Alcalde RE, Tsuji T, Matsumura T. The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int J Cancer. 2001;93:667-673.
44. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55:5195-5199.